Loading...
•
Dec 31, 2021
Cullinan Oncology Q4 2021 Earnings Report
Reported fourth quarter and full year 2021 financial results and provided a corporate update.
Key Takeaways
Cullinan Oncology reported its fourth quarter and full year 2021 financial results. Clinical trials for CLN-619 and CLN-049 were initiated, and an HPK1 degrader collaboration with Mount Sinai was established. The company finished the year with over $430 million in cash and investments.
Reported compelling data from the ongoing Phase 1/2a trial of CLN-081.
FDA granted CLN-081 Breakthrough Therapy Designation.
Initiated clinical trials for CLN-619 and CLN-049.
Expanded pipeline with an HPK1 degrader collaboration with the Icahn School of Medicine at Mount Sinai.
Forward Guidance
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.
Positive Outlook
- Cullinan’s beliefs and expectations regarding our preclinical and clinical development plans
- clinical trial designs
- clinical and therapeutic potential
- strategy of our product candidates
- our ability to evaluate strategic opportunities to accelerate development timelines
Challenges Ahead
- uncertainty regarding the timing and results of regulatory submissions
- success of our clinical trials and preclinical studies
- risks related to our ability to protect and maintain our intellectual property position
- risks related to manufacturing, supply, and distribution of our product candidates
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...